Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

Pathway for Softgel vs Tablet Comparison [Design Issues]

posted by jag009 – NJ, 2018-05-18 18:33 (2159 d 15:27 ago) – Posting: # 18786
Views: 2,453

Hi,

❝ However I have a case where a BE study was conducted comparing Metronidazole tablet (Reference) with Metronidazole soft gel (test). Both were IR. Is this acceptable?

Have you read this guidance? FDA

John

Complete thread:

Bioequivalence of IR vs MR tablet heritage 2018-05-05 06:25
- Consider 505(b)(2) Pathway bebac_fan 2018-05-05 17:08
  - Pathway for Softgel vs Tablet Comparison Obinoscopy 2018-05-15 19:04
    - Pathway for Softgel vs Tablet Comparisonjag009 2018-05-18 16:33

Admin contact
22,984 posts in 4,822 threads, 1,651 registered users;
46 visitors (0 registered, 46 guests [including 2 identified bots]).
Forum time: 10:00 CEST (Europe/Vienna)

You can’t fix by analysis
what you bungled by design. Richard J. Light, Judith D. Singer, John B. Willett

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz